^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

    Excerpt:
    ...- Patient must have BRAF V600 mutation positive based on report from Clinical Laboratory Improvement Act (CLIA) certified laboratory...
    Trial ID:
    NCT04221438
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

    Excerpt:
    ...- Histologically confirmed diagnosis of metastatic melanoma with the presence of the B-Raf proto-oncogene, serine/threonine kinase (BRAFV600) mutation...
    Trial ID:
    NCT02263898
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

    Excerpt:
    ...- Unresectable advanced or metastatic malignant melanoma with BRAF [Rapidly Accelerated Fibrosarcoma isoform B] V600 mutation;...
    Trial ID:
    BERINGMELANOMA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

    Excerpt:
    ...- Cohort A: BRAF V600 mutant melanoma patients with progressive central nervous system (CNS) metastases....
    Trial ID:
    NCT05026983
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Treat Rev
    Title:

    Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis

    Published date:
    11/01/2022
    Excerpt:
    Among double combination therapies, encorafenib + binimetinib showed high probabilities of being better for all efficacy and safety endpoints….Encorafenib + binimetinib has a favourable efficacy profile compared to other double combination therapies and a favourable safety profile compared to both double and triple combination therapies.
    DOI:
    10.1016/j.ctrv.2022.102463
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Treat Rev
    Title:

    Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis

    Published date:
    09/06/2022
    Excerpt:
    The objective of this study was to estimate the relative efficacy and safety of targeted therapies for the treatment of metastatic melanoma using a network meta-analysis (NMA)….Encorafenib + binimetinib has a favourable efficacy profile compared to other double combination therapies and a favourable safety profile compared to both double and triple combination therapies.
    DOI:
    10.1016/j.ctrv.2022.102463
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2022
    Title:

    826P - Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial

    Published date:
    09/05/2022
    Excerpt:
    Median OS was 18.4m (95% CI: 12.1-NR) with 93.3, 72.7 & 62.3% of pts alive at 6, 12 & 18m respectively….EB achieve a significant iRR in pts with symptomatic brain BRAF mut MBM…
    Trial ID:
    EBRAIN-MEL
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Dermatol
    Title:

    Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy

    Published date:
    11/11/2020
    Excerpt:
    ...we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy...The objective response rate (ORR) for the total cohort was 68.4%...our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen.
    DOI:
    10.1111/1346-8138.15688
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Pharmacy Times
    Title:

    Treatment With Encorafenib/Binimetinib Leads to Improved, Longer Responses in Patients With BRAF Mutations

    Published date:
    04/22/2020
    Excerpt:
    Patients with BRAF mutations administered treatment with encorafenib/binimetinib (EB) trended toward improved and longer responses than patients who received dabrafenib/trametinib (DT).
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Melanoma Res
    Title:

    Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib

    Published date:
    05/28/2021
    Excerpt:
    ...68-year-old woman with metastatic melanoma who had received multiple treatment courses including combination immunotherapy and combination MAPK-targeted therapy presented with a brainstem metastasis and demonstrated a complete response upon initiation of encorafenib and binimetinib
    DOI:
    10.1097/CMR.0000000000000750